Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new?

 

Launch of accredited Type 1 Childhood Diabetes CME

A new EACCME-accredited CME activity Individual Patient Management in Type 1 Childhood Diabetes has launched on epgonline.org. Intended for medical professionals involved in the management of young patients with type 1 diabetes, this module consists of six sessions, each covering a different aspect of managing psychosocial issues in type 1 childhood diabetes.

Explore at your own pace and test your knowledge using the interactive learning exercises. The activity is totally free, and on completion you will be awarded 1 European CME credit (ECMEC). 

 

Anti-Infectives Knowledge Network (AIKN) CDI Updates

Recently updated with new reports and policy updates as well as key perspectives on Clostridium difficile infection (CDI), the Anti-Infectives Knowledge Network shares expertise and experience in the area of anti-infectives.

This educational resource is an initiative by Astellas Pharma EMEA. Please remember to return often to read the news, clinical insights, and essential information from the latest anti-infective congresses.

January 2015 FDX/15/0003/EU

 

Bedwetting CME

This free CME activity covers the best practice management of nocturnal enuresis through three case study-led modules, including a more severe and complex patient scenario. It is intended for Urologists, Paediatricians, Primary Care Providers and General Practitioners looking to improve their understanding and management of bedwetting.

 

Accredited Obesity CME

The EACCME accredited European Obesity Initiative eCME module – Understanding Obesity, is freely accessible to healthcare professionals. Upon successful completion, participants will be awarded 2 European CME credits (ECMECs) and have a broad understanding of the epidemiology, contributory factors and management options for patients with obesity.

 

Type 2 Diabetes accredited CME

‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ is EACCME accredited and awarded 1 European CME credit (ECMEC). There are 3 modules:

  • A Review of Newer Therapies for Type 2 Diabetes in Combination with Insulin; John Wilding (Chair)
  • Identifying and Managing the Psychosocial Aspects of Type 2 Diabetes Mellitus; Richard Holt (Faculty)
  • Potential Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin: Interactive Case Discussion; Bernard Charbonnel (Faculty)
     

Latest News

Sorin Group to merge with Cyberonics Inc.

27-Feb-2015

Sorin S.p.A. a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics Inc. a medical device company with core expertise in neuromodulation, announced their merger plan to create a new global leader in ...

FDA approves Toujeo (insulin glargine [rDNA origin]) for treatment of Type 1 and Type 2 Diabetes-Sanofi

27-Feb-2015

Sanofi announced that the FDA approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be ...

FDA panel recommends approval for KXL System + combined riboflavin for corneal ectasia and ketatoconus- Avedro

27-Feb-2015

The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel recommended approval of combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking from Avedro.Photrexa ...

AMG 416 meets endpoint in Phase III study in hyperparathyroidism in CKD-Amgen

27-Feb-2015

Amgen has announced results from the head-to-head Phase III study comparing AMG 416 with cinacalcet for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis. The study met the ...

CEP 33237 filed at FDA for treatment for chronic pain-Teva

27-Feb-2015

Teva Pharmaceutical Industries Ltd., announced that the FDA has accepted for review the New Drug Application (NDA) for the company’s hydrocodone bitartrate extended-release (ER) tablets formulated with Teva’s proprietary abuse deterrence technology ...

EU approves Xadago for Parkinsons-Newron Pharma

27-Feb-2015

The European Commission has approved the use of Xadago (safinamide), from Newron Pharmaceuticals, for the treatment of idiopathic Parkinson’s disease. The drug has been approved for mid-to late-stage fluctuating patients as add-on therapy to a stable ...

Boston Scientific plan to buy AMS pelvic device unit from Endo Pharma for $2 billion.

27-Feb-2015

Boston Scientific Corp is close to buying Endo International PLC's AMS medical device unit, a deal that could value the business at around $2 billion, The companies are aiming to finalize an agreement within a matter of weeks, the people said this ...

Recent Updates

Drugs

Clinical Guidelines

Guidelines on Prostate Cancer

Early and locally advanced breast cancer: Diagnosis and treatment

Medical Journals

How growth due to infant nutrition influences obesity and later disease risk

A comparison of obesity related adipokine concentrations in knee and shoulder osteoarthritis patients

The implications of obesity on pregnancy outcome

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial

epgonline.org Social